Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2016  |  Volume : 29  |  Issue : 2  |  Page : 341-348

Detection of circulating lamin B1 and glypican-3 for early diagnosis of hepatocellular carcinoma patients


Department of Clinical Pathology, Faculty of Medicine, National Liver Institute, Menoufia University, Menoufia Governorate, Egypt

Correspondence Address:
Heba S Mohammed Ghanem
Department of Clinical Pathology, National Liver Institute, Menoufia University, 5 Taiseer street, Shebein El kom, Menoufia Governorate, 32511
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1110-2098.192442

Rights and Permissions

Objective: To assess circulating lamin B1 (LMNB1) mRNA and glypican-3 cytotoxic T lymphocytes (CTLs) as markers for early detection of hepatocellular carcinoma (HCC). Background: HCC is the fifth most common form of cancer worldwide and the third most common cause of cancer-related deaths. HCC often occurs in the background of a cirrhotic liver. In recent years, surveillance strategies in patients at a higher risk of HCC have led to the diagnosis of the disease at much earlier stages. Patients in early stages have a much higher chance of curative response with different treatment options. Materials and methods: The study included 50 participates, of which 13 were patients with posthepatitis C liver cirrhosis (group I), 13 were patients with early stages of HCC (group IIa), 14 were patients with late stages of HCC (group IIb), and 10 were healthy volunteers with matched age and sex as a control group (group III). The patients were selected from the outpatient clinic and inpatient department of the National Liver Institute, Menoufiya University. LMNB1 mRNA was assessed by reverse transcription-PCR and glypican3 CTLs by flow cytometry and then we compared that with α±-feto protein. Results: Glypican3 CTLs can be used for early detection of HCC patients with 100% specificity and sensitivity. In addition, LMNB1 mRNA can be used in early detection of HCC with specificity and sensitivity 92 and 100%, respectively. Conclusion: Circulating LMNB1 mRNA and glypican3 CTLs can be used as markers for early detection of HCC patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed642    
    Printed2    
    Emailed0    
    PDF Downloaded79    
    Comments [Add]    

Recommend this journal